Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Financings In Brief: Alfacell

Executive Summary

Alfacell: Completes private placement of approximately $6 mil. The placement included the issuance of 1.6 mil. shares of common stock and 325,000 three-year warrants convertible to one share of common stock each at an exercise price of $7.50 per share. With the placement, Bloomfield, N.J.-based Alfacell will have approximately 13.5 mil. shares outstanding and operating funds for two years. Alfacell's lead product is the ribonuclease protein Onconase, which is in Phase III trials for advanced pancreatic cancer and a Phase II trial for malignant mesothelioma...
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS028336

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel